Cardiome To Release 2008 First Quarter Results
To access the conference call, please dial 416-641-6117 or 866-299-6655.There will be a separate dial-in line for analysts on which we will respond toquestions at the end of the call. The webcast can be accessed throughCardiome's website at www.cardiome.com.
Webcast and telephone replays of the conference call will be availableapproximately two hours after the completion of the call through June 13,2008. Please dial 416-695-5800 or 800-408-3053 and enter code 3261188 followedby the number sign to access the replay.
About Cardiome Pharma Corp.
Cardiome Pharma Corp. is a product-focused cardiovascular drug developmentcompany with two late-stage clinical drug programs focused on atrialarrhythmia (intravenous and oral dosing), a Phase 1 program for GED-aPC, anengineered analog of recombinant human activated Protein C, and a pre-clinicalprogram directed at improving cardiovascular function.
Vernakalant (iv) is the intravenous formulation of an investigational drugbeing evaluated for the acute conversion of atrial fibrillation. Positivetop-line results from two pivotal Phase 3 trials for vernakalant (iv), calledACT 1 and ACT 3, were released in December 2004 and September 2005. Cardiome'sco-development partner Astellas Pharma US, Inc. submitted a New DrugApplication for vernakalant (iv) in December 2006. Positive top-line resultsfrom an additional Phase 3 study evaluating patients with post-operativeatrial arrhythmia, called ACT 2, were released in June 2007. An open-labelsafety study evaluating recent-onset AF patients, called ACT 4, has completed.
Vernakalant (oral) is being investigated as a chronic-use oral drug forthe maintenance of normal heart rhythm following termination of AF. Cardiomeannounced positive results from a Phase 2a pilot study for vernakalant (oral)in September 2006. A Phase 2b study for vernakalant (oral) is ongoing.
In April 2007 Cardiome acquired exclusive worldwide rights for GED-aPC forall indications. Cardiome intends to initially develop GED-aPC in cardiogenicshock, a life-threatening form of acute circulatory failure due to cardiacdysfunction, which is a leading cause of death for patients hospitalizedfollowing a heart attack.
Cardiome is traded on the Toronto Stock Exchange (COM) and the NASDAQNational Market (CRME).
Forward-Looking Statement Disclaimer
Certain statements in this press release contain forward-lookingstatements within the meaning of the Private Securities Litigation Reform Actof 1995 or forward-looking information under applicable Canadian securitieslegislation that may not be based on historical fact, including withoutlimitation statements containing the words "believe", "may", "plan", "will","estimate", "continue", "anticipate", "intend", "expect" and similarexpressions. Such forward-looking statements or information involve known andunknown risks, uncertainties and other factors that may cause our actualresults, events or developments, or industry results, to be materiallydifferent from any future results, events or developments expressed or impliedby such forward-looking statements or information. Such factors include, amongothers, our stage of development, lack of product revenues, additional capitalrequirements, risk associated with the completion of clinical trials andobtaining regulatory approval to market our products, the ability to protectour intellectual property, dependence on collaborative partners and theprospects for negotiating additional corporate collaborations or licensingarrangements and thei
You May Also Like